Conclusion Through a unique collaboration with FDA under the EAP, the BeAT-HF trial design allows for the possibility of approval of BAT, initially for symptom relief and subsequently for outcomes improvement. (Am Heart J 2018;204:139-50.) Despite significant improvements in the management of heart failure with a reduced ejection fraction (HFrEF), morbidity and mortality rates remain unacceptably high. 1, 2 This is especially true for the 70% or more of patients with HFrEF who are not eligible for cardiac resynchronization therapy. 3 One novel treatment developed to fill this continuing unmet need is the use of an implantable device capable of producing cardiac autonomic modulation. Autonomic modulation has taken 3 general approaches: spinal cord stimulation, direct vagal stimulation, and carotid baroreflex activation therapy (BAT). [4] [5] [6] [7] Results from spinal and vagal stimulation studies have been disappointing; none of the 3 randomized trials examining these methods has resulted in reduced morbidity or mortality rates. [4] [5] [6] The effects of BAT have been examined in preclinical studies, a first-in-man single-center study that focused on defining the mechanism of action of BAT, and a moderate-size prospective randomized feasibility trial (HOPE4HF) ( Table I 7-18 ). These studies showed that BAT, using afferent signaling to the brain via the carotid sinus nerve, reduces sympathetic signaling and increases parasympathetic signaling that act in aggregate to rebalance the autonomic input to the heart (Figure 1 ). In the HOPE4HF trial, BAT significantly decreased Nterminal pro-B-type natriuretic peptide (NT-proBNP), increased 6-minute hall walk distance (6MHWD), improved Minnesota Living with Heart Failure Questionnaire (MLWHF) quality of life score (QOL), and decreased the number of days hospitalized for HF after 6 months of treatment compared to nonimplanted control patients receiving optimized guideline-directed medical therapy (GDMT). 7 These clinical benefits were most pronounced in patients who were not being treated with cardiac resynchronization therapy (CRT). 17 Followup data at 12 months posttreatment showed that these findings were durable. 18 These data were used to design a pivotal, randomized clinical trial to evaluate the safety and effectiveness of BAT for HFrEF: A Randomized, Controlled Trial of Baroreflex Activation Therapy in Patients with Heart Failure and Reduced Ejection Fraction Ineligible for Resynchronization Therapy (BeAT-HF; ClinicalTrial.gov Identifier: NCT02627196).
The design and performance of pivotal trials aimed at obtaining US regulatory approval and favorable reimbursement designation for new device therapies in HFrEF pose several challenges. These include the need to exceed the effectiveness of current GDMT, a task made more difficult by continuing advances in medical therapy and better adherence to treatment guidelines; the fiscal constraint in trial size imposed by device studies compared to drug studies; and the costs associated with these trial designs. In recognition of these challenges, the United States Food and Drug Administration's (FDA) issued guidance on an Expedited Access Pathway (EAP) program for medical devices to provide a pathway that would allow the possibility to accelerate market access for promising technologies intended to treat seriously ill patients with unmet needs. 19 Subsequently, the EAP is now called the Breakthrough Devices Program following passage of the 21st Century Cures Act in late 2016. 20 The purpose of this manuscript is to (1) describe the data, process, and justification by which the BeAT-HF trial was developed in partnership with FDA under the EAP; (2) demonstrate how the EAP was used to define the final trial design; and (3) describe the unique statistical analysis and modeling using both frequentist and Bayesian analyses applied to BeAT-HF.
Methods: trial design

Overview
BeAT-HF is a prospective, randomized, 2-arm, parallelgroup trial designed to develop valid scientific evidence for the safety and effectiveness of BAT with the Barostim neo System (CVRx, Minneapolis, MN) in patients with HFrEF. The trial was designed by the Executive Steering Committee in collaboration with CVRx, Inc, and the FDA's Division for Cardiovascular Center of Device Evaluation under the EAP. 19 The trial incorporates a Bayesian adaptive sample size design and will randomize between 480 and 960 patients at up to 90 centers in the United States and as many as 20 European centers. [21] [22] [23] [24] The trial is designed to obtain 2 FDA regulatory approvals ( Figure 2 ). The Expedited Phase will measure quality of life, functional capacity, and biomarker improvements, and the Extended Phase will measure improvement in morbidity and mortality outcomes. The Expedited Phase will be an original premarket approval (PMA) submission, will occur when the 264th randomized patient completes 6 months of follow-up, and is based upon 3 intermediate end points (NT-pro BNP, 6MHWD, and QOL) as well as a positive trend in the Extended Phase end point. The Extended Phase will be submitted to FDA as PMA Supplement, examines the composite clinical outcome end point of heart failure morbidity and cardiovascular mortality (HFM&CVM), and requires randomization of at least 480 patients followed for a period of at least 2 years. The Extended Phase incorporates an adaptive sample size algorithm based upon predictive probabilities and may randomize up to 960 patients. 21, 22 This trial is expected to be completed in approximately 5 years from the time of first enrollment to end of follow-up.
Barostim neo System description, implantation technique, uptitration
The system for delivering BAT consists of a carotid sinus lead and a pulse generator (Figure 3) . The system and implant techniques have been fully described in previous publications (Table I ) and the Appendix. Device uptitration will be done from therapy activation through month 3 according to a standardized procedure described in previous publications (Table I, Appendix) .
Patients
The inclusion and exclusion criteria are presented in Table II . Key eligibility requirements include HFrEF patients with New York Heart Association (NYHA) Class III (or NYHA Class II if recent episode of NYHA Class III); left ventricular ejection fraction (LVEF) ≤35%; not eligible for or treated with CRT; elevated natriuretic peptides or prior HF hospitalization; and on optimized, stable HF treatment. Subsequent to the original FDA approval, new eligibility amendments were approved and implemented. These are described in detail in the Supplemental Materials Appendix 1 and are accompanied by a description of the rationale used to justify these changes.
Follow-up and procedures
The trial timeline and structure for BeAT-HF are illustrated in Figure 2 and Table III . Following successful screening, baseline information is collected, and then patients are randomized 1:1 to receive BAT + GDMT or GDMT alone. "Time zero" for each patient is established as the intended surgical implant date, which is provided by the center in order to receive a randomization code from the central electronic data collection system. Permuted block randomization techniques are used within each clinical center to balance randomization by center. Patients randomized to BAT + GDMT undergo implant of the BAT system within a maximum of 14 days after randomization (or 28 days for first 2 proctored implantations). All patients regardless of randomization assignment are followed in an identical manner according to a predefined schedule determined by implant date, which is either the intended implant date (GDMT arm) or actual implant date (BAT + GDMT arm). Visits occur biweekly for the first 2 months postimplant. From months 3 to 24, visits are quarterly, with biannual visits thereafter. Medical therapy may be adjusted at any visit as dictated by patient need.
Expedited Access Pathway
Several elements of the EAP guidance were incorporated into the trial design. Eligibility for EAP designation required demonstration that HFrEF patients constituted seriously ill patients with an unmet need. A 2-stage regulatory submission approach was developed.
The Expedited Phase original PMA includes the evaluation of the effects of BAT on 3 intermediate end points (NT-pro BNP, 6MHWD, and MLWHF QOL) after 6 months of follow-up measured in the first 264 patients randomized ( Figure 2 ). As described below, the effects of BAT will be examined on each of the 3 individual 6-month end points; there must be a statistically significant 
Carotid Baroreceptor Stimulation Efferent Signaling
Physiology of baroreflex activation, adapted from Floras. 32 Stimulation of the carotid arterial baroreceptor produces afferent signaling to the brain via the carotid sinus nerve, resulting in an integrated autonomic nervous system response that reduces sympathetic signaling and increases parasympathetic signaling that act in aggregate to rebalance the autonomic efferent signaling to the heart, blood vessels, and kidneys. Baroreflex activation is hypothesized to modulate the deleterious effects of chronic HF by decreasing heart rate, causing reverse remodeling and vasodilation, decreasing blood pressure and renin secretion, and increasing diuresis. BP, arterial blood pressure; HR, heart rate.
improvement in each end point. In addition, based on the HFM&CVM end point events that occur up to the time of the Expedited Phase analysis, there must be a sufficiently high Bayesian predictive probability (PP) of passing the Extended Phase hypothesis test at the end of the study (positive trend) to apply for regulatory approval under an indication for symptom improvement. For the Expedited PMA submission, end points will provide evidence that the BAT reduces HF symptoms under the following label indication: reduction of the symptoms of HF in patients who remain symptomatic (NYHA Functional Class II/III), LVEF ≤35%, despite GDMT, neither eligible for nor treated with CRT. The Extended Phase will evaluate the effects of BAT on the HFM&CVM end point at the end of the trial on all randomized patients (Figure 2 ). For the FDA PMA Supplement submission at the end of the Extended Phase, end points provide evidence for a general treatment effect for HFrEF under the following label indication: indicated for treatment of patients with HF who remain symptomatic (NYHA Functional Class II/III), LVEF ≤35% despite GDMT, including patients neither eligible for nor treated with CRT to reduce HF mortality and hospitalization.
A statistical analysis plan was created using a frequentist approach to analyze the Expedited Phase end points (part of symptom-based PMA), and the final analysis of the Extended Phase Morbidity and Mortality end point (and PMA Supplement). A Bayesian approach was created for the PP calculations for HFM&CVM trend analysis at the end of the Expedited Phase and for the adaptive design for interim sample size decisions. Methods used in the Bayesian analyses are presented in Supplemental Materials Appendix 1.
End points, statistical methods, and sample size
Expedited Phase safety end point. The safety end point assesses the incidence of major adverse cardiovascular and neurological events (MANCE) that are related to the system or the procedure in patients implanted with the BAT system. MANCE events include cardiovascularrelated death, stroke, cardiac arrest, acute myocardial infarction, acute decompensated HF, hypertensive crisis, severe complications of HF treatment, systemic and pulmonary thromboembolism, infection requiring explantation of any portion of the BAT system, cranial nerve damage that either is permanent (not resolved within 12 months from onset) or requires an invasive Sufficient morbidity and mortality data collected on all subjects
• Full morbidity and mortality • Totality of evidence
M&M Interim Analysis Sample Size Re-estimation
Extended Phase
BeAT-HF trial design: FDA EAP approved approach. BeAT-HF is organized around 2 complimentary stages to obtain 2 regulatory approvals. Please see manuscript text for details.
intervention to correct, and events requiring nonelective major restorative procedures (specific to the placement of the Barostim neo System; eg, operation for wound hematoma at the surgical site). Suspected cranial nerve damage will be assessed by an otolaryngologist for the existence of a functional neurological deficit. It should be noted that patients may undergo an evaluation by an otolaryngologist prior to randomization at the discretion of the site investigator and after randomization if any symptoms develop after implant. All MANCE will be adjudicated by independent adverse events committees. The assumptions for the safety end point of the Expedited Phase were based on results from the HOPE4HF feasibility trial of BAT in HFrEF which demonstrated a MANCE event-free rate of 97.2% with a lower 95% confidence bound of 91.4%. Using a 1-sided exact binomial hypothesis test with .05 α, 85% power, an expected event-free rate of 93%, and performance goal of 85%, the required sample size is 100 BAT + GDMT patients (Table IV) .
Expedited Phase effectiveness end point. Effectiveness end points of the Expedited Phase examine changes in NT-proBNP, 6MHW, and MLWHF score at 6 months relative to baseline in the BAT + GDMT group versus the GDMT-alone group. Effectiveness of the Expedited Phase will require corroboration by a positive trend for BAT to improve HFM&CVM outcomes, which is defined below in the Bayesian interim analysis section. Each of the 3 effectiveness end points will be individually assessed, and all must demonstrate superiority of BAT + GDMT versus GDMT alone at a 2-sided α level of .05. The statistical test and assumptions are shown in Table IV , but in summary, the testing procedure is identical for 6MHWD and MLWHF score: mean improvements will be analyzed using an analysis of covariance linear regression model that includes treatment group and baseline value as a continuous covariate. Mean improvement will be compared between groups with a Wald test. Because the third intermediate end point, NT-proBNP, is unlikely to be normally distributed, the relative percentage change from baseline will be compared between the BAT + GDMT group and the GDMT-alone group using a 2-sided Wilcoxon rank-sum test.
Sample sizes for these end points were based on the number of patients required to obtain at least an 80% chance meeting all 3 end points. This analysis will emphasize the congruence between the 3 individual end points. 26 Data considered in the sample size estimates are presented in Table IV and include observed results from the HOPE4HF phase 2 trial of BAT in HFrEF, data from published studies that relate changes in each metric to clinically meaningful outcomes, and expected effects on specific end point thresholds. 7, 17, 18, 25 Results of the literature review that summarizes these data were 
Wireless Programmer
Barostim neo technology platform for BAT. The Barostim neo platform consists of an implantable pulse generator, a carotid sinus lead, and a wireless programmer. The characteristics of each are listed on the slide and in the manuscript text. or at time of screening (enrollment is defined as the date the subject provided written consent) 3. Left ventricular ejection fraction ≤35% within 45 d prior to randomization 4. HF accompanied by (must meet 1 of the following): BNP ≥400 or NT-proBNP ≥1600 For subjects with documented permanent or persistent atrial fibrillation, BNP ≥600 or NT-proBNP ≥2400 pg/mL OR BNP ≥100 or NT-proBNP ≥400 AND prior hospitalization for HF within 12 m For subjects with documented permanent or persistent atrial fibrillation, BNP ≥150 or NT-proBNP ≥600 pg/mL within 45 d prior to randomization Note: Screening BNP/NT-proBNP must be measured locally and in an outpatient setting at a time when the subject is thought to be clinically stable. Revision: HF accompanied by BNP ≥100 or NT-proBNP ≥400 or an HF hospitalization in the past 12 m Note: HF hospitalization may include an overnight hospital or hospital-based observation unit stay with a primary diagnosis of HF or an emergency department visit with a primary diagnosis of HF. 5. On optimal, stable, GDMT (per the AHA/ACC guidelines) for the treatment of HF for at least 4 wk prior to obtaining any postconsent screening parameters:
• No more than a 100% increase or a 50% decrease of the dosage of any 1 medication other than a diuretic
• Medication changes within a drug class are allowed as long as the equivalent dosage is within the limits specified above.
• Unrestricted changes in diuretics are allowed as long as the subject remains on a diuretic. 6. 6MHW ≥150 m AND ≤400 m within 45 d prior to randomization. 7. The artery planned for the Barostim implant must meet both of the following criteria:
• At least 2 independent measures of resting heart rate of either b60 or N100 beat/min.
Revision: Recurring resting heart rate of either b60 or N100 beat/min via clinic measurements within 45 d prior to randomization (note: heart rate b60 beat/min is not applicable to subjects with an implanted device capable of pacing.) 8. At least 2 independent measures of systolic blood pressure b100 mm Hg Revision: recurring symptomatic hypotension within 45 d prior to randomization 9. Significant uncontrolled symptomatic bradyarrhythmias or unstable ventricular arrhythmias 10. Subjects with any surgery that has occurred, or is planned to occur, within 45 d of the Barostim neo implant procedure. This includes pacemaker or ICD implants or battery replacements. presented to and discussed with FDA and recently published. 26 Each effectiveness end point will be evaluated for a significant advantageous treatment effect with a 2-sided type I error of 5%. Based on results from the feasibility trial of BAT for HFrEF, a sample size of 264 is expected to provide a sufficient sample size after attrition to yield power of 92% for NT-proBNP, 92% for 6HWD, and 96% for the MLWHF QOL. The product of these 3 powers is approximately 81%, assuring sufficient power even if the end points are uncorrelated. Extended Phase HFM&CVM primary end point. The Extended Phase end point examines changes in the rate of HFM&CVM. HFM includes recurrent hospital or hospitalbased observation unit or emergency room visits, with a primary diagnosis of HF, as well as left ventricular assist device and cardiac transplantation. All HFM&CVM events will be adjudicated by an independent Clinical Events Committee blinded to the randomization assignment. The rate of adjudicated events will be compared between the BAT + GDMT group and the GDMT-alone group using a negative binomial recurrent events model. The model will adjust for the number of HF hospitalizations 12 months prior to enrollment to account for baseline heterogeneity in patients. To pass this end point, the BAT + GDMT group must exhibit a statistically lower event rate than the GDMTalone group at an α level of .022. A critical value of .022 will be used to account for a small degree of type I error inflation due to adaptively selecting the final sample size.
The initial sample size of 480 randomized for the Extended Phase effectiveness end point was determined by simulation. Simulations assumed an accrual rate of 240 patients per year, events for the control group occur at a rate of 0.4 event per patient per year, and BAT treatment reduces the rate of constituent outcomes by 30% versus control (0.28 event per patient per year). It was anticipated that 35% of all primary end point events would be censoring events (death, cardiac assist device, and/or heart transplant) and that 10% of patients per year would be lost to follow-up or withdrawal. For the negative binomial distribution, an overdispersion parameter of 16 was assumed. The sample size may be adapted if necessary, as defined below in the Bayesian interim analysis section. All prospective end points will be evaluated on an intention-to-treat basis.
Design operating characteristics
Table V presents operating characteristics for the trial. Under different assumptions about the size of the BAT treatment effect, it shows the probability of demonstrating a positive trend at the end of the Expedited Phase. Under those assumptions, it also shows the probabilities of whether a positive trend (PP N55%) is demonstrated at any of the interim analyses and/or the estimated HFM&CVM treatment effect is statistically significant (1-sided P b .022) at the end of the trial. The first row in Table V assumes a 0% reduction in the rate of HFM&CVM end point events (the null scenario) and shows that the probability of a type I error for the final HFM&CVM end point analysis is 2.2%, whereas the probability of exceeding the 55% PP target is 21.0% at the end of the Expedited Phase and 30.0% over all interim analyses. Under the primary design assumption of a 30% reduction, there is a 96.8% chance the observed treatment effect for the HFM&CVM end point will be statistically significant at the end of the trial, and the probability of exceeding the 55% PP target is 84.0% at the end of the Expedited Phase and 98.2% over all interim analyses. Under the 30% treatment effect scenario, there is only a 2.4% chance that the 55% PP target will be met at any of the interim analyses, but the final HFM&CVM end point analysis will not be statistically significant. There is a 1.0% chance that the final HFM&CVM end point analysis will be statistically significant despite not meeting the 55% PP target at any of the interim analyses.
Economic modeling
A final health economics cost-effectiveness analysis will be performed upon the completion of the trial and will also be used to support a budget impact model for a hypothetical US payer. The following measurements will be used in these analyses: (1) resource use, (2) outcomes (including survival and risk prediction), and (3) QOL and health-state utilities. Additional economic measurements will include costs of BAT system, implantation procedure, follow-up, medications, implant replacement, hospitalizations, other cardiovascular implantable devices, physician visits, emergency department visits, optimal medical treatment patients following withdrawal, and postacute care. Further methodologic details are presented in the Supplemental Material Appendix 1.
Blinding
The BeAT-HF trial is a controlled and randomized open trial. HFM&CVM outcome evaluation by the end point adjudication committee will be blinded in both the Expedited and the Extended Phases, complying with the Prospective Open Blinded Evaluation design.
Trial oversight and funding
Trial conduct, scientific integrity, and all relevant publications will be overseen by the Executive Steering Committee. Adverse event adjudications will be performed by the Adverse Events Committee and Clinical Events Committee, as appropriate, and consistent with their charters. A Data Monitoring Committee will have the responsibility to protect patient safety by reviewing unblinded events throughout the trial. The membership of each committee is detailed in the addendum.
This study is being funded by CVRx to support the research study. All of the authors are either employees of CVRx, Berry Consultants, or NAMSA or are consults to CVRx as members of the Executive Steering Committee. No other individual or organization not listed as an author contributed in any substantive way to the writing or editing of the paper or performance of any analyses described herein. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.
Unmet need
Review of current data from epidemiologic studies and from the most recent randomized controlled trials demonstrated that despite the most current GDMT (including all drug and device categories) for patients with HFrEF, the 5-year mortality rate ranges from 25% to 35%, HF hospitalization rate ranges from 15% to 30%, and functional disability as measured by 6MHWD and QOL remained pronounced.
1,2 Therefore, BAT for HFrEF studied in the BeAT-HF trial fulfilled the EAP criteria of a "de novo medical device intended for unmet medical need for a life threatening or irreversibly debilitating disease or condition".
Discussion
There are several unique features of the BeAT-HF trial design described in this manuscript. First, the data, process, and justification by which the BeAT-HF trial was developed in partnership with FDA under the EAP are defined. Second, how the EAP was used to define the final trial design was determined. Third, the unique statistical analysis and modeling using both frequentist and Bayesian analyses applied to BeAT-HF were presented in detail. BeAT-HF provided a practical case study illustrating the process by which a trial was developed within the FDA EAP structure; the data and methods needed to obtain protocol approval; and the collaborative process between FDA, sponsor, and trial leadership/oversight committees needed to accomplish these tasks. The BeAT-HF trial design within the EAP construct has clear strengths and advantages. These include economic considerations, collaborations in trial design, innovation in end point definitions, interim adaptability models, and emphasis on QOL/symptomatic outcomes.
Economic feasibility
Recent pharmacologic outcomes trials in HFrEF such as for ivabradine 27 and angiotensin-neprilysin inhibitors 28 have required a several-thousand patient sample size to achieve a definitive outcome. Although such a burden may be manageable in a trial of medical therapy, it is impractical for device therapy. The cost of a device trial with a sample size of a few hundred patients can easily exceed $100 million. Although it is critical to maintain definitive testing standards, the relatively smaller sample sizes impose conditions under which devices may be required to have a more potent effect than drugs. All of these factors significantly limit innovation. It is in part in recognition of these challenges that FDA created the EAP program for medical devices to accelerate market access for promising technologies intended to treat seriously ill patients with unmet needs. The EAP program benefits include close collaboration with FDA in trial design; priority status for FDA; possible panel review of PMA application; and, perhaps most importantly, the possibility of PMA on the basis of surrogate/intermediate end points. Thus, the EAP program was developed with the intention to shorten time cycles, bring product to market in reduced time, and reduce overall costs. The extent to which EAP improves the economic feasibility of innovation in device therapy will be determined by the results of BeAT-HF and other ongoing EAP designed studies. As of January 5, 2018, FDA has received 94 EAP requests and granted 52 requests. Following passage of the 21st Century Cures Act, all EAP devices will be reviewed by FDA under the Breakthrough Devices Program.
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Early focus on patient-centered symptomatic outcomes
The use of intermediate end points in the Expedited Phase of BeAT-HF prioritizes a focus on patient-centered symptomatic outcomes. These end points provide an evaluation of functional capacity, quality of life, and a change in a serum biomarker associated with HF symptom status and prognosis. The importance of development of therapies that improve patient-centered symptomatic outcomes has been emphasized by the FDA, industry, and key opinion leaders in HF in recently published white papers [29] [30] [31] and in HF guidelines. 1, 2 Patients and their care providers have "voted with their feet" regarding prioritizing QOL over quantity of life. For example, the rationale for the continued widespread use of continuous intravenous inotropes, despite the increased rates of mortality associated with their use, is based on improved measures of QOL and symptomatic status. In the context of the EAP-facilitated BeAT-HF trial design, the Expedited Phase prioritizes patient-centered symptomatic outcomes; however, the additional requirement for a positive HFM&CVM trending in the Expedited Phase will prevent the approval of a device that improves symptoms at the cost of increased morbidity and/or mortality. The advantages to the EAP-facilitated BeAT-HF trial design described above must be viewed in balance with recognized limitations that challenge such a trial design. These challenges include the predictive capacity of intermediate end points, the objectivity of end points using nonblinded nonimplanted controls, and statistical limitations of the Bayesian modeling. In addition, the possibility of drop-ins (crossovers) or dropouts (discontinuation of therapy and/or lost to follow-up) should be proactively kept to a minimum.
Value/predictability of intermediate end points
The value and limitations of each of the 3 intermediate end points that will be used in the BeAT-HF trial have been described in detail in a recent publication. 26 In symptomatic HFrEF, statistically significant absolute and relative decreases in natriuretic peptides may be taken as objective mechanistic and prognostic markers indicative of clinical benefit and are frequently but not universally associated with improved outcomes. When congruent with statistically significant improvements in other patient-centered outcomes such as 6MWD and healthrelated QOL scores, these changes are reasonable evidence of clinically meaningful benefit of a given treatment. However, although clear associations between intermediate end points and HFM&CVM outcomes have been identified in previous studies in HFrEF, there have been no prospectively studied development programs that have demonstrated predictability of any intermediate end points to be predictive of phase III mortality outcomes. In addition, whether and to what extent positive results using patient-centric intermediate end points will be sufficient to satisfy a PMA advisory panel, payers, and clinical adoption remain an unanswered question.
Validity and predictability of Bayesian modeling
Given the long history of using frequentist methods for analyzing and presenting results of clinical trials in medical journals, the use of traditional frequentist analysis procedures for each of the Expedited and Extended Phase end points provides the advantage of presenting results and P values that will be familiar to regulators, advisory panel members, journal reviewers, and journal readers alike, making the trial results easier to interpret and evaluate. The use of Bayesian statistics is limited to predicting future trial data based on accumulating partial trial data, which is an area where the unique ability of Bayesian methodology to incorporate uncertainty in statistical model parameters due to partial data is of critical importance. Using Bayesian methods to adaptively select the smallest trial sample size that will give a suitably high chance of passing the Extended Phase hypothesis test while controlling the overall frequentist type I error allows for an efficient trial timeline. Both Bayesian and frequentist methods are used according to the strengths of each method. Although Bayesian methods provide assurance that uncertainty in the statistical model parameters will be fully accounted for in the model predictions, it is possible that the full complexity of the outcomes data will not be adequately described by the specific joint negative binomial model selected for use in this trial. Ongoing changes in the typical patient enrolled in the trial, the evolving standard medical therapy provided for HF patients, and potential for time-varying dynamics in the therapeutic impact of BAT therapy on patients could result in some degree of miscalibration of the predictive statistical model when predicting future data based on partial observed data. These potential risks will be addressed through sensitivity analyses rather than by use of a more complex model due to decreasing returns in prediction accuracy afforded by increasing model complexity.
Maintaining trial integrity between the Expedited and the Extended Phases
Several additional potential limitations must be considered, as follows: How can the study integrity remain secure after interim evaluations of ongoing data collection? How can we prevent crossover to intervention by control if interim results made public are positive? If the Expedited Phase data are positive but the Extended Phase data are neutral or vice versa, how will these results be interpreted and acted upon? Would an Expedited Phase positive result but an Extended Phase noninferior HFM&CVM result be sufficient to justify use of BAT? Several aspects of the BeAT-HF trial design do in fact mitigate some of the challenges raised above (Figure 4 ). All 480 patients will be randomized by the time the first 264 patients have been followed for 6 months. Therefore, recruitment will not be impacted by release of the Expedited Phase data. Publication of the 6-month data on the first 264 patients will censor the data trending of mortality and morbidity. By the time that the expedited PMA occurs, the Extended Phase follow-up should be approaching completion. Some of the concerns raised above must await the completion of the BeAT-HF trial to be addressed.
Limitations
Perhaps the most significant challenge to the trial design centered around the issue of blinding/unblinding in the clinical design. Several factors effected the final choice in addition to fiscal constraints, as follows: Ethical challenge: Half the subject would have undergone the risk of implantation without having any potential benefit from the device being turned on for up to 3-5 years. It was presumed that it was possible that some institutional review boards would disapprove the study due to this risk/benefit profile. Impact on enrollment: Subjects faced with the potential of having an implanted BAT device that remains off for up to 3-5 years would likely markedly reduce subject willingness to participate, potentially lengthening the trial. Protocol compliance: It might be challenging for investigators to maintain compliance with the protocol, such as leaving the device off despite deteriorating health. Imperfect blinding: A sham surgery with the BAT device may not result in complete and effective blinding for the subjects, as the device is programmed just below the point of clinically observed stimulation (which is targeted to measure this threshold). Robust end points: The core end points chosen, such as NT-proBNP and morbidity and mortality, are robust despite an unblinded study and should provide objective evidence of benefit.
Conclusions
Based on a unique collaboration with FDA under the EAP, using both frequentist and Bayesian statistical modeling, and an innovative adaptive trial design, the BeAT-HF trial design allows for the possibility of an expedited approval of BAT for improvement in symptom relief and disease severity biomarker followed by an extended phase for outcomes improvement.
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